Author

C Lee

Observed name: C. Lee

Institution: Zentalis Pharmaceuticals (United States)

Observed institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Louisville, University of Calgary, Dana-Farber Cancer Institute, Aichi Cancer Center, The Cancer Institute Hospital, National Cancer Center Hospital East, Japanese Foundation For Cancer Research, Zentalis Pharmaceuticals (United States), National Cancer Center Hospital, Kindai University

OpenAlex ID: A5113311984

Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study

2019 · S Modi, J Tsurutani, et al. · Cancer Research · 27

Endometrial development during the transition to menopause: preliminary associations with follicular dynamics

2020 · A. Baerwald, H. Vanden Brink, et al. · Climacteric · 8

Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study

2019 · S Verma, J Shahidi, et al. · Cancer Research · 4

35P The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates

2024 · J. Ma, X. Guo, et al. · Annals of Oncology · 3

Works count: 4

Citation count: 42

H-index: 3

I10-index: 1